Dr. Hwang on the State of Treatment in Metastatic Prostate Cancer

Video

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the state of treatment in metastatic prostate cancer.

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses the state of treatment in metastatic prostate cancer.

In metastatic castration-sensitive prostate cancer, multiple agents have been shown to improve survival, including docetaxel, abiraterone acetate (Zytiga), enzalutamide (Xtandi), and apalutamide (Erleada). As such, patients should be offered 1 of those agents, says Hwang. As time goes on, more data are going to emerge with combination treatments which may help answer the question of whether patients need docetaxel and a novel hormonal agent, adds Hwang.

In metastatic castration-resistant prostate cancer, olaparib (Lynparza) should be considered for use in patients with homologous recombination repair defects. Right now, the agent would be used off-label in anticipation of an approval, says Hwang. Patients with bone metastases should be given bone-protecting agents, says Hwang. Additionally, radium-223 dichloride (Xofigo) plus abiraterone is not recommended in this patient population, concludes Hwang.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD